Next 10 |
2024-06-17 09:02:04 ET Solar Acquisition Corp (SLRX) announced stock split at a ratio of 1-for-8 on 2024-06-17 ... Full story available on KlickAnalytics.com
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C...
2024-06-12 08:27:01 ET More on Salarius Pharmaceuticals Seeking Alpha’s Quant Rating on Salarius Pharmaceuticals Historical earnings data for Salarius Pharmaceuticals Financial information for Salarius Pharmaceuticals Read the full article on Seeking...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...
2024-03-25 07:36:50 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to dive into the biggest pre-market stock movers that traders need to know about on Monday morning! Moving stocks this morning are cannabis legalization, drug approval, a d...
2024-03-22 16:17:56 ET More on Salarius Pharmaceuticals Salarius's CEO David Arthur steps down Seeking Alpha’s Quant Rating on Salarius Pharmaceuticals Financial information for Salarius Pharmaceuticals Read the full article on Seeking Alpha Fo...
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant Expense-reduction Measures to Extend Cash Runway HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) ...
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , announ...
HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center (MDACC or MD Anderson) is now listed as active and recruiting on...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NYSE Market:
Salarius Pharmaceuticals Inc. Website:
2024-06-17 09:02:04 ET Solar Acquisition Corp (SLRX) announced stock split at a ratio of 1-for-8 on 2024-06-17 ... Full story available on KlickAnalytics.com
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (C...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) , a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect...